<DOC>
	<DOC>NCT02504463</DOC>
	<brief_summary>This study will determine the pharmacokinetics (PK) of [14c]-samidorphan in healthy male volunteers.</brief_summary>
	<brief_title>A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Body mass index (BMI) of greater than/equal to 19 and less than/equal to 32 kg/m^2 at screening (minimum weight of 50.0 kg) Generally good health Subjects must agree to reduce the risk of a female partner becoming pregnant during the study and for 30 days after the last dose of the study drug by abstinence from heterosexual relationships or use of a reliable contraceptive method Additional criteria may apply Clinically significant illness within 30 days History of alcohol or opioid dependence, or positive urine toxicological screen for marijuana, cocaine, amphetamines, opioids, barbiturates, and benzodiazepines History of oral or gastrointestinal disease Irregular bowel or bladder function History of allergy or hypersensitivity to opioid medications or opioid antagonists (eg, naltrexone, naloxone) Current or pending legal charges or probation that would interfere with study conduct Use of alcohol within 24 hours prior to admission or urine positive test for alcohol at screening or admission Tobacco or nicotine use within 90 days Anticipated need for prescription medicines during the study period Additional criteria may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>Samidorphan</keyword>
	<keyword>ALKS 33</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>